Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sabby Management Thinks Cel-Sci is a Good Investment

Sabby Management: In a recent SEC filing, Sabby Management disclosed initiating a passive position in CEL-SCI Corporation (NYSEMKT:CVM) through purchasing 4.25 million shares. The stake amasses 8.7% of the company, and has a value of $3.57 million at the current price of Cel-Sci’s stock. Sabby did not mention ownership of Cel-Sci shares in its latest 13F.


A couple of days ago, Cel-Sci, which is a late-stage oncology company, disclosed the pricing of its underwritten public offering of common stock and warrants, which amounts to $1 per unit, which includes one share and one warrant to purchase one share. The company is currently at risk of being delisted from the NYSE MKT. Earlier in July, the market in a note announced the company that it is not in compliance with the listing standards. The company had the deadline until September 30 to regain compliance, the date being prolonged until the end of October, the company said in a statement.

Disclosure: none

Recommended Reading:

Orange Capital Follows Citadel Into Cherry Hill Mortgage Investment

Outerwall, Pandora & Achillion All Targets of Mega-Hedge Funds

The ‘Smart Money’ Loves The 500% Upside On This Biopharma Stock